How Polivy Stacks Up on Side Effects
Polivy (polatuzumab vedotin), approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), combines with bendamustine and rituximab (Pola-BR). Common side effects include neutropenia (42%), thrombocytopenia (26%), anemia (22%), fatigue (20%), diarrhea (18%), and peripheral neuropathy (16%) from the Phase 2 GO29365 trial.[1] Infusion reactions occur in 40% of patients, mostly mild.[1] Compared to other DLBCL treatments, Polivy shows higher neuropathy risk due to its antibody-drug conjugate mechanism but lower rates of severe infections.
Polivy vs. Standard R-CHOP
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is first-line for DLBCL. Polivy adds to BR for later lines, but head-to-head data is limited. R-CHOP causes neutropenia (60-70%), nausea (50%), hair loss (60%), and neuropathy (15-20%) from vincristine.[2] Polivy has less nausea (10%) and no alopecia but doubles neuropathy risk and adds unique risks like pneumonia (14%). Grade 3+ adverse events are similar at ~80% for both.[1][2]
Polivy vs. CAR-T Therapies Like Yescarta or Breyanzi
CAR-T cells (axicabtagene ciloleucel or lisocabtagene maraleucel) treat refractory DLBCL post-multiple lines. Cytokine release syndrome (CRS) hits 94% with Yescarta (13% grade 3+), neurologic events 64% (31% grade 3+), and infections 30-40%.[3] Polivy avoids CRS entirely, with lower neurotoxicity (no ICANS reported) but higher cytopenias. CAR-T has 20-30% treatment-related mortality risk in first year; Polivy's is under 5%.[1][3] Patients unfit for CAR-T toxicity often get Polivy.
Polivy vs. Other Antibody-Drug Conjugates Like Enhertu
Enhertu (trastuzumab deruxtecan) is for breast cancer, but Adcetris (brentuximab vedotin), another CD30-targeted conjugate, treats Hodgkin lymphoma and some B-cell lymphomas. Both cause neuropathy (Polivy 40-50% all-grade vs. Adcetris 67%) and neutropenia (Polivy higher at 42% grade 3+).[1][4] Polivy's target (CD79b) leads to more GI issues; Adcetris has more rash.
What Patients Report Most About Side Effects
Real-world data from FDA FAERS shows Polivy linked to 1,200+ neuropathy reports, infections, and cytopenias through 2023, with 15% serious.[5] Patients on forums note manageable fatigue but persistent tingling; discontinuation rates are 20-30% due to neuropathy.[1] Manage with dose delays or gabapentin.
Key Factors Influencing Side Effect Risks
Older patients (>75) on Polivy see 90% grade 3+ events vs. 70% in younger groups.[1] Prophylactic G-CSF cuts neutropenia. No major drug interactions worsen toxicity beyond CYP3A4 inducers.
[1]: Polivy Prescribing Information, Genentech (https://www.gene.com/download/pdf/polivy_prescribing.pdf)
[2]: SEER data and NCCN guidelines on R-CHOP toxicity (https://www.nccn.org/guidelines)
[3]: Yescarta Label, Kite Pharma (https://www.yescarta.com/)
[4]: Adcetris Label, Seagen (https://www.adcetris.com/)
[5]: FDA Adverse Event Reporting System (FAERS) Public Dashboard (https://fis.fda.gov/sense/app/9525e8ed-35e5-41d2-a9cb-2d865e6a7f0e/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis)